Updates are available Correction dated 2021-05-13
Click to view Correction: https://doi.org/10.1038/s41587-021-00939-y
-
Authors
Petri, Karl http://orcid.org/0000-0002-9624-3976
Zhang, Weiting
Ma, Junyan
Schmidts, Andrea http://orcid.org/0000-0001-7035-1584
Lee, Hyunho
Horng, Joy E. http://orcid.org/0000-0001-7702-7381
Kim, Daniel Y. http://orcid.org/0000-0002-6273-7310
Kurt, Ibrahim C. http://orcid.org/0000-0003-3927-0991
Clement, Kendell http://orcid.org/0000-0003-3808-0811
Hsu, Jonathan Y. http://orcid.org/0000-0002-1342-5628
Pinello, Luca
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
Joung, J. Keith http://orcid.org/0000-0001-5630-5645
Yeh, Jing-Ruey Joanna http://orcid.org/0000-0002-7768-4901
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (417577129)
China Scholarship Council
John Hansen Research Grant by the DKMS
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG009490, R35 HG010717, RM1 HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118158, R01 GM134069)
United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-17-2-0042)
- License Information
-
More Information
Article History
Received: 7 August 2020
Revised: 14 March 2021
Accepted: 16 March 2021
First Online: 29 April 2021
Change Date: 13 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-021-00939-y
Competing interests
: J.K.J. has financial interests in Beam Therapeutics, Chroma Medicine (formerly known as YKY, Inc.), Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, SeQure Dx, Transposagen Biopharmaceuticals and Verve Therapeutics (formerly known as Endcadia). K.P. has a financial interests in SeQure Dx, Inc.. L.P. has financial interests in Edilytics, SeQure Dx, Inc. and Excelsior Genomics. K.P. and D.Y.K. are paid consultants to Verve Therapeutics. K.C. is an employee, shareholder and officer of Edilytics, Inc. The interests of J.K.J., L.P., K.C., K.P. and D.Y.K. were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital and University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in TCR2 and Century Therapeutics, and has served as a consultant for multiple companies involved in cell therapies. The remaining authors declare no competing interests.
